About Ipamorelin Prescribed.

What this site is

Ipamorelin Prescribed is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on ipamorelin, a selective growth hormone secretagogue. Our angle is simple and a little unusual: we lead with the newest studies. Where most write-ups recycle the same decade-old talking points, we put the 2024-2026 findings up front and work backward to the founding science. Everything is sourced, and every quantitative claim links to a study on the Ipamorelin references page.

What this site is not

We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product, and we do not link to anyone who does. Our work is editorial commentary on publicly available science — nothing on this site is a prescription, a protocol, or a purchase pathway.

About the name: 'Prescribed' is editorial framing, not a service claim. It points at a real tension in how ipamorelin is discussed — marketed and sometimes clinic-administered as though it were a settled therapy — versus what regulators have actually approved, which is nothing. Ipamorelin has never been approved as a drug anywhere, it is not a prescribable medication, and no one can prescribe it to you. Naming that gap is the entire point of the framing.

How we handle the evidence

We describe research findings using 'studied at X dose in this species' language, and we never present a human dosing recommendation or an efficacy promise. When community reports appear — on the Ipamorelin effects page — they are clearly labeled anecdotal and kept separate from cited findings. When a study used a related compound rather than ipamorelin itself (a class-level safety signal, say, or a CJC-1295 dataset), we say so plainly so nothing gets misattributed. The goal is a digest you can trust precisely because it draws the lines honestly.